Sign in3 stories
The all-stock deal pairs Aethlon with private biotech North Immunology and an oversubscribed $180 million private placement to fund development of NOR-101 in atopic dermatitis.
SEC filing
The company revised severance terms for its CEO/CFO and Chief Medical Officer so that qualifying post-merger terminations trigger lump-sum, not installment, payments.
SEC filing
The company reported fiscal first quarter results and said early biomarker signals from its Hemopurifier oncology study support continued evaluation, while cash stood at about $4.9 million as of June 30, 2026.
SEC filing